John A. Thompson

22.7k total citations · 5 hit papers
111 papers, 12.4k citations indexed

About

John A. Thompson is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John A. Thompson has authored 111 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 32 papers in Immunology and 31 papers in Molecular Biology. Recurrent topics in John A. Thompson's work include Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (27 papers) and Immunotherapy and Immune Responses (16 papers). John A. Thompson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (27 papers) and Immunotherapy and Immune Responses (16 papers). John A. Thompson collaborates with scholars based in United States, Australia and South Africa. John A. Thompson's co-authors include Michael B. Atkins, Charles M. Balch, Douglas S. Reintgen, Kelly M. McMasters, John M. Kirkwood, John F. Thompson, Daniel G. Coit, Jeffrey E. Gershenwald, Shailender Bhatia and Merrick I. Ross and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

John A. Thompson

110 papers receiving 12.1k citations

Hit Papers

Final Version of the American Joint Committee on Cancer S... 2001 2026 2009 2017 2001 2001 2019 2002 2008 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
    2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →
  2. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
    2001 1.8k citations Charles M. Balch, Seng‐Jaw Soong et al. Journal of Clinical Oncology profile →
  3. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
    2019 1.5k citations Filipe Martins, Sofiya Latifyan et al. Nature Reviews Clinical Oncology profile →
  4. Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
    2002 941 citations John A. Thompson et al. profile →
  5. Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
    2008 704 citations Naomi Hunder, John A. Thompson et al. profile →

Peers

John A. Thompson
Wyndham H. Wilson United States
Svetomir N. Markovic United States
Stefania Pittaluga United States
Antônio C. Buzaid United States
Alessandro Testori Italy
Célèste Lebbé France
David C. Linch United Kingdom
Ulrich Keilholz Germany
Jane L. Messina United States
Leo I. Gordon United States
Wyndham H. Wilson United States
John A. Thompson
Citations per year, relative to John A. Thompson John A. Thompson (= 1×) peers Wyndham H. Wilson

Countries citing papers authored by John A. Thompson

Since Specialization
Citations

This map shows the geographic impact of John A. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Thompson more than expected).

Fields of papers citing papers by John A. Thompson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Thompson. The network helps show where John A. Thompson may publish in the future.

Co-authorship network of co-authors of John A. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Thompson. A scholar is included among the top collaborators of John A. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Thompson. John A. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lü, Yang, Dongfeng Tan, Kathryn Bollin, et al.. (2023). Sclerosing mesenteritis following immune checkpoint inhibitor therapy. Journal of Cancer Research and Clinical Oncology. 149(11). 9221–9227. 4 indexed citations
2.
Tachiki, Lisa, Daniel S. Hippe, Evan Hall, et al.. (2023). Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunology Immunotherapy. 72(11). 3839–3850. 9 indexed citations
3.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations
4.
Réa, Andréa, et al.. (2021). Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma. JAAD Case Reports. 17. 49–51. 6 indexed citations
5.
Carlino, Matteo S., Alexander M. Menzies, Victoria Atkinson, et al.. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research. 26(19). 5086–5091. 30 indexed citations
6.
Martins, Filipe, Sofiya Latifyan, Gerasimos P. Sykiotis, et al.. (2019). Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology. 16(9). 563–580. 1544 indexed citations breakdown →
7.
Thompson, John A., Robert J. Motzer, Ana M. Molina, et al.. (2018). Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research. 24(18). 4399–4406. 48 indexed citations
8.
Rodler, Eve T., Brenda F. Kurland, Melissa Griffin, et al.. (2016). Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer. Clinical Cancer Research. 22(12). 2855–2864. 69 indexed citations
9.
Bhatia, Shailender, Brendan D. Curti, Marc S. Ernstoff, et al.. (2014). Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. Journal for ImmunoTherapy of Cancer. 2(1). 2–2. 46 indexed citations
10.
Lord, James D., Robert C. Hackman, John A. Thompson, et al.. (2009). Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells. Digestive Diseases and Sciences. 55(5). 1396–1405. 84 indexed citations
11.
Hutchins, Laura F., James Moon, Joseph I. Clark, et al.. (2007). Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 110(10). 2269–2275. 6 indexed citations
12.
Lush, Richard M., Jeannine S. McCune, Leticia Tetteh, et al.. (2005). The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 56(6). 578–584. 24 indexed citations
13.
Balch, Charles M., Antônio C. Buzaid, Seng‐Jaw Soong, et al.. (2003). New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Seminars in Surgical Oncology. 21(1). 43–52. 93 indexed citations
14.
Schwartz, Anna L., John A. Thompson, & Nehal Masood. (2002). Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and Methylphenidate. Oncology nursing forum. 29(7). E85–E90. 108 indexed citations
15.
Motzer, Robert J., Ashok Rakhit, John A. Thompson, et al.. (2001). Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma. Journal of Interferon & Cytokine Research. 21(4). 257–263. 83 indexed citations
16.
McCracken, Michael S., Jack E. Lemons, Kurt R. Zinn, John A. Thompson, & Dale S. Feldman. (2001). Radioimaging of implants in rats using Tc‐99m‐MDP. Clinical Oral Implants Research. 12(4). 372–378. 18 indexed citations
17.
Reiff, Donald A., Stacey S. Kelpke, Loring W. Rue, & John A. Thompson. (2001). Acidic Fibroblast Growth Factor Attenuates the Cytotoxic Effects of Peroxynitrite in Primary Human Osteoblast Precursors. PubMed. 50(3). 433–439. 19 indexed citations
18.
Benyunes, Mark, Carl M. Higuchi, Catherine Lindgren, et al.. (1995). Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.. PubMed. 16(2). 283–8. 53 indexed citations
19.
Thompson, John A., et al.. (1989). Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.. Journal of Clinical Oncology. 7(5). 629–637. 144 indexed citations
20.
Beastall, G. H., et al.. (1987). Insulin-dependent ketosis-resistant diabetes in Ethiopia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 81(4). 539–543. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wyndham H. Wilson Breakdown of academic impact, for papers by Svetomir N. Markovic Breakdown of academic impact, for papers by Stefania Pittaluga Breakdown of academic impact, for papers by Antônio C. Buzaid Breakdown of academic impact, for papers by Alessandro Testori Breakdown of academic impact, for papers by Célèste Lebbé Breakdown of academic impact, for papers by David C. Linch Breakdown of academic impact, for papers by Ulrich Keilholz Breakdown of academic impact, for papers by Jane L. Messina Breakdown of academic impact, for papers by Leo I. Gordon
Rankless by CCL
2026